Comparison of fixed versus traditional weight‐based dosing of rasburicase in a pediatric population

Background The American Society of Clinical Oncology guidelines recommend rasburicase for the treatment of pediatric patients with hyperuricemia at risk of tumor lysis syndrome (TLS) using a weight‐based dose of 0.1–0.2 mg/kg once daily for 1–7 days. However, there has been a trend in practice due t...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer 2018-10, Vol.65 (10), p.e27236-n/a
Main Authors: Savva, Dimitrios A., Herrera, Nicole, Rohatgi, Radha
Format: Article
Language:English
Subjects:
Children
dosing
fixed
Hematology
Hyperuricemia
Lysis
Malignancy
Oncology
Patients
Pediatrics
rasburicase
Success
tumor lysis syndrome
Uric acid
weight‐based
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The American Society of Clinical Oncology guidelines recommend rasburicase for the treatment of pediatric patients with hyperuricemia at risk of tumor lysis syndrome (TLS) using a weight‐based dose of 0.1–0.2 mg/kg once daily for 1–7 days. However, there has been a trend in practice due to recent data showing benefit using a fixed‐dose approach. The purpose of this study was to evaluate the efficacy and safety between fixed and weight‐based dosing of rasburicase in a pediatric population. Procedure This was a retrospective chart review of 48 patients from January 1, 2007 to August 31, 2016 at Children's National Health System. Patients less than 18 years old with a documented diagnosis of a malignancy and baseline uric acid level were included; patients less than 30 kg at the time of rasburicase administration were excluded. Results The primary endpoint of this study was the treatment success of normalization of uric acid level (
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.27236